CommentThe coming of age of MEK
References (11)
- et al.
Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial
Lancet
(2012) - et al.
Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF
Cell
(2010) - et al.
BRAF mutation predicts sensitivity to MEK inhibition
Nature
(2006) - et al.
Genetic analysis of Ras signalling pathways in cell proliferation, migration and survival
EMBO J
(2010) - et al.
RAS oncogenes: the first 30 years
Nat Rev Cancer
(2003)
There are more references available in the full text version of this article.
Cited by (6)
Melanoma genotypes and phenotypes get personal
2013, Laboratory InvestigationDysregulation of RNA polymerase I transcription during disease
2013, Biochimica et Biophysica Acta - Gene Regulatory MechanismsCitation Excerpt :In some cases, signaling down the RAS/RAF/MEK/ERK and PI3K/AKT/mTOR cascades converge to regulate Pol I transcription leading to cancer. The HER2 and EGF receptors themselves are also subject to amplification and activating mutation in cancer [190,195,197,203]. The overactivity of these receptors can “hyperactivate” the RAS and PI3K pathways resulting in the stimulation of rDNA transcription.
Diabetic retinopathy and ocular melanoma: How far we are?
2020, Applied Sciences (Switzerland)Novel drugs against non-small-cell lung cancer
2014, Current Opinion in Oncology
Copyright © 2012 Elsevier Ltd. All rights reserved.